RELATED CONTENT
NEWS
- Biogen/Elan hope updated Tysabri label will lend confidence to patients/prescribers
- Focus on Almirall: partnering, new products and mature markets are key targets
- Conditional European approval for Fampyra for MS walking disability
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients

